Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.77 |
| ▸ | F2 | P00734 | 4/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023222 | 0.95 | F10 (0.85) | F10F2ABCB11ST14 | |
| Hydrochloric Acid SCHEMBL1025286 | 0.94 | F10 (0.84) | F10F2ABCB11ST14 | |
| SCHEMBL3479937 | 0.90 | F10 (0.78) | F10F2ABCB11ST14 | |
| SCHEMBL8236763 | 0.89 | F10 (0.76) | F10F2ABCB11ST14 | |
| SCHEMBL87006 | 0.87 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL3479842 | 0.85 | F10 (0.70) | F10F2ABCB11ST14 | |
| Trifluoroacetic Acid SCHEMBL77386 | 0.84 | F10 (0.68) | F10F2ABCB11ST14 | |
| SCHEMBL79715 | 0.82 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL24177659 | 0.82 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL13698655 | 0.82 | F10 (1.00) | F10F2ABCB11ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945634-B1 | PHENYLENEBISOXAZOLIDINE DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | BAYER SCHERING PHARMA AG (DE) | 2011-01-19 | — | — | EP | disclosed |
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | BAYER HEALTHCARE AG (DE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041646-A1 | Phenylene-Bis-Oxazolidine Derivatives and Their Use as Anticoagulants | SELP, SERPINC1, F2 | F10 346/4885F2 3/4885ABCB11 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.